Michael Levitt, MD
Glaucoma Specialist · Tampa, FLNPI 1720074974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 25.4% of the total.
Across 197 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$743
- Alcon$526
- Glaukos Corporation$412
- Sun Pharmaceutical Industries Inc.$339
- Bausch & Lomb, A Division Of Bausch Health US, LLC$339
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$1703%
- Food & beverage$5,60597%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $1,471 |
| Mallinckrodt Hospital Products Inc. | 29 | $743 |
| Alcon | 17 | $526 |
| Glaukos Corporation | 7 | $412 |
| Sun Pharmaceutical Industries Inc. | 12 | $339 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $339 |
| Kala Pharmaceuticals, Inc. | 15 | $285 |
| Bausch & Lomb Americas Inc. | 7 | $229 |
| Rxsight Inc | 2 | $180 |
| Sight Sciences, Inc. | 3 | $176 |
| Notal Vision, Inc. | 1 | $170 |
| Ivantis, Inc | 2 | $146 |
| NEW World Medical,inc. | 1 | $142 |
| Amgen | 6 | $126 |
| Thea Pharma Inc. | 5 | $105 |
| Aerie Pharmaceuticals, Inc. | 6 | $94 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Dompe US, Inc. | 1 | $34 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Baxter Healthcare | 1 | $27 |
| Eyepoint US, Inc. | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$388
- XEN$225
- iDoseTR$162
- RXSIGHT INJECTOR HANDPIECE$149
- RXSIGHT CONTACT LENS$149
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$149
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$149
- RXSIGHT INJECTOR CARTRIDGE$149
- Ahmed Glaucoma Valve$142
- Kahook Dual Blade$142
- Hydrus Microstent$132
- MIEBO$125
- XIIDRA$125
- LUMIGAN$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- PROLENSA$122
- OMNI(R) SURGICAL SYSTEM (US)$120
- NGENUITY$120
- Luxor$120
- BROMSITE$104
How this compares
$5,794 in reported general payments places this provider in the 60th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 348 | $207,212 |
| RhopressaNetarsudil Mesylate | 179 | $115,028 |
| RocklatanNetarsudil Mesylat/Latanoprost | 165 | $111,719 |
| CombiganBrimonidine Tartrate/Timolol | 224 | $110,191 |
| Alphagan PBrimonidine Tartrate | 152 | $72,732 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 117 | $44,027 |
| RestasisCyclosporine | 43 | $43,963 |
| ProlensaBromfenac Sodium | 96 | $33,814 |
| Methazolamide | 89 | $27,518 |
| VyzultaLatanoprostene Bunod | 63 | $27,121 |
| Prednisolone Acetate | 384 | $11,662 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 588 | $9,928 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 65 | $9,393 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 60 | $8,818 |
| Brimonidine Tartrate | 306 | $7,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $1,471 | $434,097767 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $94 | $226,747344 claims |
| AlconSimbrinza | $526 | $44,027117 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $339 | $33,81496 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $229 | $27,12163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Tampa
- Hirah KhanTampa$2K
- Kimberly JunTampa$2K
- Analisa ArosemenaMiami Beach$438K
- Steven VoldWinter Garden$413K
- Matthew BrinkPalm Beach Gardens$159K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.